JP2022507103A5 - - Google Patents
Info
- Publication number
- JP2022507103A5 JP2022507103A5 JP2021525303A JP2021525303A JP2022507103A5 JP 2022507103 A5 JP2022507103 A5 JP 2022507103A5 JP 2021525303 A JP2021525303 A JP 2021525303A JP 2021525303 A JP2021525303 A JP 2021525303A JP 2022507103 A5 JP2022507103 A5 JP 2022507103A5
- Authority
- JP
- Japan
- Prior art keywords
- corticosteroid
- dose
- hsd1 inhibitor
- urinary
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024063590A JP2024098991A (ja) | 2018-11-20 | 2024-04-10 | コルチコステロイドを投与する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862769932P | 2018-11-20 | 2018-11-20 | |
| US62/769,932 | 2018-11-20 | ||
| PCT/US2019/046449 WO2020106337A1 (en) | 2018-11-20 | 2019-08-14 | Methods for administering corticosteroids |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024063590A Division JP2024098991A (ja) | 2018-11-20 | 2024-04-10 | コルチコステロイドを投与する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022507103A JP2022507103A (ja) | 2022-01-18 |
| JP2022507103A5 true JP2022507103A5 (https=) | 2022-08-23 |
| JP7472122B2 JP7472122B2 (ja) | 2024-04-22 |
Family
ID=70774135
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021525303A Active JP7472122B2 (ja) | 2018-11-20 | 2019-08-14 | コルチコステロイドを投与する方法 |
| JP2024063590A Pending JP2024098991A (ja) | 2018-11-20 | 2024-04-10 | コルチコステロイドを投与する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024063590A Pending JP2024098991A (ja) | 2018-11-20 | 2024-04-10 | コルチコステロイドを投与する方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12220412B2 (https=) |
| EP (1) | EP3883578A4 (https=) |
| JP (2) | JP7472122B2 (https=) |
| CN (1) | CN113329754A (https=) |
| AU (2) | AU2019384074B2 (https=) |
| BR (1) | BR112021009653A2 (https=) |
| CA (1) | CA3120339A1 (https=) |
| IL (2) | IL319327A (https=) |
| MX (2) | MX2021005801A (https=) |
| WO (1) | WO2020106337A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022076398A1 (en) * | 2020-10-07 | 2022-04-14 | Surface Ophthalmics, Inc. | Pharmaceutical kits and their use for treating dry eye disease |
| AU2019384074B2 (en) | 2018-11-20 | 2025-04-10 | Sparrow Pharmaceuticals, Inc. | Methods for administering corticosteroids |
| KR20210141448A (ko) | 2018-12-27 | 2021-11-23 | 서피스 아프샐믹스 인코포레이티드 | 안구 표면 질환을 치료하기 위한 안과용 약학 조성물 및 방법 |
| SG11202108529WA (en) * | 2019-02-08 | 2021-09-29 | Sanofi Sa | Biotechnological optimization of microorganisms for the 1,2-dehydrogenation of steroids |
| US12310981B2 (en) | 2021-05-10 | 2025-05-27 | Surface Ophthalmics, Inc. | Use of chondroitin sulfate for relieving ocular pain |
| US12440510B2 (en) | 2021-05-10 | 2025-10-14 | Surface Ophthalmics, Inc. | Use of chondroitin sulfate for relieving ocular pain |
| EP4525983A4 (en) * | 2022-05-16 | 2025-09-03 | Sparrow Pharmaceuticals Inc | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS |
| WO2023225507A1 (en) * | 2022-05-16 | 2023-11-23 | Sparrow Pharmaceuticals, Inc. | Methods and compositions for treating glucocorticoid excess |
| AU2024348222A1 (en) * | 2023-09-27 | 2026-04-16 | Sparrow Pharmaceuticals, Inc. | Methods and compositions for treating glucocorticoid-mediated diseases |
| GB202408335D0 (en) | 2024-06-11 | 2024-07-24 | Astrazeneca Ab | Therapies for wound treatment |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3907821A (en) | 1974-11-20 | 1975-09-23 | Upjohn Co | 2-{8 3-{8 1-(DIMETHYLAMINO)CYCLOPROPYL{8 -4H-1,2,4-triazol-4-yl{8 {0 benzophenone |
| US4577020A (en) | 1983-01-25 | 1986-03-18 | The Upjohn Company | Aminoalkyl and aminoalkenyl triazoles as anti-psychotic agents |
| IL84093A (en) | 1986-10-09 | 1992-09-06 | Ciba Geigy Ag | Aralkyl-4h-1,2,4-triazole derivatives,their preparation and pharmaceutical compositions containing them |
| GB0101447D0 (en) * | 2001-01-19 | 2001-03-07 | Univ Edinburgh | Regulation of glucocorticoid concentration |
| GB0107383D0 (en) | 2001-03-23 | 2001-05-16 | Univ Edinburgh | Lipid profile modulation |
| AUPR878201A0 (en) | 2001-11-09 | 2001-12-06 | Fujisawa Pharmaceutical Co., Ltd. | New compounds |
| AU2002361861A1 (en) | 2001-12-21 | 2003-07-30 | Rhode Island Hospital | SELECTIVE 11Beta-HSD INHIBITORS AND METHODS FOR USE THEREOF |
| AU2003207717B9 (en) | 2002-02-01 | 2009-05-07 | Merck & Co., Inc. | 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia |
| AR040241A1 (es) | 2002-06-10 | 2005-03-23 | Merck & Co Inc | Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia |
| WO2004014881A2 (en) | 2002-08-09 | 2004-02-19 | Astra Zeneca Ab | '1,2,4'oxadiazoles as modulators of metabotropic glutamate receptor-5 |
| JO2397B1 (en) | 2002-12-20 | 2007-06-17 | ميرك شارب اند دوم كوربوريشن | Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors |
| US20060094699A1 (en) * | 2003-04-11 | 2006-05-04 | Kampen Gita Camilla T | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy |
| EP1615647B1 (en) | 2003-04-11 | 2010-01-20 | High Point Pharmaceuticals, LLC | Pharmaceutical use of fused 1,2,4-triazoles |
| ATE482747T1 (de) | 2003-04-11 | 2010-10-15 | High Point Pharmaceuticals Llc | Neue amide derivate und deren pharmazeutische verwendungen |
| WO2004089367A1 (en) | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | Pharmaceutical use of substituted 1,2,4-triazoles |
| CN1795181A (zh) | 2003-05-29 | 2006-06-28 | 麦克公司 | 用作11β－羟基类固醇脱氢酶－1抑制剂的三唑衍生物 |
| US7683059B2 (en) | 2003-10-28 | 2010-03-23 | Amgen Inc. | Triazole compounds and uses related thereto |
| JP2005170939A (ja) | 2003-11-20 | 2005-06-30 | Takeda Chem Ind Ltd | 糖尿病の予防・治療剤 |
| EP1696915A1 (en) | 2003-12-19 | 2006-09-06 | Pfizer, Inc. | Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-hsd-1) for the treatment of diabetes and obesity |
| CA2549385A1 (en) | 2003-12-22 | 2005-07-21 | Eli Lilly And Company | Triazole, oxadiazole and thiadiazole derivative as ppar modulators for the treatment of diabetes |
| WO2005097759A1 (en) | 2004-03-29 | 2005-10-20 | Merck & Co., Inc. | Diaryltriazoles as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 |
| US7880001B2 (en) | 2004-04-29 | 2011-02-01 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme |
| US8415354B2 (en) | 2004-04-29 | 2013-04-09 | Abbott Laboratories | Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
| US8022225B2 (en) | 2004-08-04 | 2011-09-20 | Taisho Pharmaceutical Co., Ltd | Triazole derivative |
| CN101014578B (zh) | 2004-09-16 | 2011-01-19 | 安斯泰来制药有限公司 | 三唑衍生物或其盐 |
| US20090093463A1 (en) | 2004-11-02 | 2009-04-09 | Agouron Pharmaceuticals Inc. | Novel compounds of substituted and unsubtituted adamantyl amides |
| WO2006068199A1 (ja) | 2004-12-22 | 2006-06-29 | Mochida Pharmaceutical Co., Ltd. | 代謝的に安定な３－オキシ－１，２，４－トリアゾール誘導体 |
| JPWO2006080533A1 (ja) | 2005-01-31 | 2008-06-19 | 持田製薬株式会社 | ３−アミノ−１，２，４−トリアゾール誘導体 |
| CN101198605A (zh) | 2005-06-16 | 2008-06-11 | 辉瑞大药厂 | N-(吡啶-2-基)-磺酰胺衍生物 |
| WO2006134481A1 (en) | 2005-06-16 | 2006-12-21 | Pfizer Inc. | Inhibitors of 11-beta hydroxysteroid dehydrogenase type 1 |
| CA2610903A1 (en) | 2005-06-16 | 2006-12-21 | Pfizer Inc. | N-(pyridin-2-yl)-sulfonamide derivatives |
| WO2007007688A1 (ja) | 2005-07-08 | 2007-01-18 | Mochida Pharmaceutical Co., Ltd. | ３,５－ジアミノ－１,２,４－トリアゾール誘導体 |
| CA2620179C (en) | 2005-08-16 | 2013-10-29 | Icagen, Inc. | Inhibitors of voltage-gated sodium channels |
| UY29796A1 (es) | 2005-09-29 | 2007-04-30 | Astrazeneca Ab | Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor |
| JPWO2007105753A1 (ja) | 2006-03-16 | 2009-07-30 | アステラス製薬株式会社 | トリアゾール誘導体またはその塩 |
| US20070224298A1 (en) | 2006-03-23 | 2007-09-27 | Talbott Shawn M | Inhibiting 11(beta)-hsd1 with citrus flavonoids |
| US7435833B2 (en) | 2006-04-07 | 2008-10-14 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme |
| TWI465439B (zh) | 2008-07-03 | 2014-12-21 | Astellas Pharma Inc | 三氮唑衍生物或其鹽 |
| EP2243494A1 (en) * | 2009-04-22 | 2010-10-27 | OntoChem GmbH | Pharmaceutical composition, comprising a steroid-dehydrogenase-reductase inhibitor, and a mineralocorticoid receptor antagonist. |
| WO2011068927A2 (en) | 2009-12-04 | 2011-06-09 | Abbott Laboratories | 11-β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11B-HSD1) INHIBITORS AND USES THEREOF |
| GB201003734D0 (en) * | 2010-03-05 | 2010-04-21 | Univ Strathclyde | Delayed prolonged drug delivery |
| UA112418C2 (uk) | 2010-09-07 | 2016-09-12 | Астеллас Фарма Інк. | Терапевтичний болезаспокійливий засіб |
| AU2013231230A1 (en) * | 2012-03-13 | 2014-08-07 | AbbVie Deutschland GmbH & Co. KG | Method for selecting or identifying a subject for V1B antagonist therapy |
| EP3166610B1 (en) * | 2014-07-09 | 2022-11-02 | Eip Pharma, LLC | Methods for treating neurologic disorders |
| CR20170456A (es) | 2015-04-07 | 2018-06-13 | Intercept Pharmaceuticals Inc | Composiciones farmacéuticas para terapias combinadas |
| US10648506B2 (en) | 2016-07-07 | 2020-05-12 | Raul Mendoza | Walking rig creeper interface |
| WO2018117063A1 (ja) | 2016-12-20 | 2018-06-28 | アステラス製薬株式会社 | 焦燥性興奮治療剤 |
| AU2019384074B2 (en) | 2018-11-20 | 2025-04-10 | Sparrow Pharmaceuticals, Inc. | Methods for administering corticosteroids |
| EP3821892A1 (en) | 2019-11-12 | 2021-05-19 | University of Leeds | (s)-2-(1-(5-(cyclohexylcarbamoyl)-6-(propylthio)pyridin-2-yl)piperidin-3-yl) acetic acid for use in treating wounds |
| EP3878446A1 (en) | 2020-03-09 | 2021-09-15 | Universite De Geneve | Hsd11b1 inhibitors for use in immunotherapy and uses thereof |
| WO2023225507A1 (en) | 2022-05-16 | 2023-11-23 | Sparrow Pharmaceuticals, Inc. | Methods and compositions for treating glucocorticoid excess |
| EP4525983A4 (en) | 2022-05-16 | 2025-09-03 | Sparrow Pharmaceuticals Inc | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS |
-
2019
- 2019-08-14 AU AU2019384074A patent/AU2019384074B2/en active Active
- 2019-08-14 IL IL319327A patent/IL319327A/en unknown
- 2019-08-14 CA CA3120339A patent/CA3120339A1/en active Pending
- 2019-08-14 CN CN201980076112.6A patent/CN113329754A/zh active Pending
- 2019-08-14 BR BR112021009653-1A patent/BR112021009653A2/pt unknown
- 2019-08-14 JP JP2021525303A patent/JP7472122B2/ja active Active
- 2019-08-14 WO PCT/US2019/046449 patent/WO2020106337A1/en not_active Ceased
- 2019-08-14 EP EP19886299.7A patent/EP3883578A4/en active Pending
- 2019-08-14 MX MX2021005801A patent/MX2021005801A/es unknown
- 2019-08-14 US US17/289,516 patent/US12220412B2/en active Active
- 2019-08-14 IL IL283069A patent/IL283069B2/en unknown
-
2021
- 2021-05-17 MX MX2025002836A patent/MX2025002836A/es unknown
-
2024
- 2024-04-10 JP JP2024063590A patent/JP2024098991A/ja active Pending
- 2024-12-13 US US18/980,242 patent/US20250205227A1/en active Pending
-
2025
- 2025-04-30 AU AU2025203033A patent/AU2025203033A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022507103A5 (https=) | ||
| US20250205227A1 (en) | Methods for administering corticosteroids | |
| JP5913136B2 (ja) | 糖質コルチコイド感作物質としてのプロゲストーゲンの使用方法 | |
| Hilderson et al. | Treatment of renal sarcoidosis: is there a guideline? Overview of the different treatment options | |
| Seo | Perioperative glucocorticoid management based on current evidence | |
| JP2020520889A5 (https=) | ||
| JP2013518908A5 (https=) | ||
| MXPA04003266A (es) | Combinaciones para el tratamiento de desodrdenes inmuno-inflamatorios. | |
| WO2008087437A1 (en) | Treatment of corticoid-resistant asthma or copd with p38 map kinase inhibit (eg. sb2035809) | |
| JP2023542345A5 (https=) | ||
| EP2701744A1 (en) | Combination therapy | |
| RU2021113995A (ru) | Способы введения кортикостероидов | |
| US20120309722A1 (en) | Therapeutic regimens for the treatment of immunoinflammatory disorders | |
| Babaoğlu et al. | Therapeutic mechanisms of glucocorticoids, their administration and chronotherapy | |
| JP7033454B2 (ja) | Ａｅｒｄ／喘息におけるトロンボキサン受容体拮抗薬 | |
| Papi et al. | Fluticasone propionate/formoterol: A fixed-combination therapy with flexible dosage | |
| Bissell et al. | Glucocorticoids | |
| TW201726145A (zh) | 用於維持皮質類固醇滑液濃度之皮質類固醇調配物 | |
| Deepalakshmi et al. | A Comprehensive Review on Corticosteroids | |
| Anandabaskar | Adrenocorticosteroids and Their Antagonists | |
| US3231468A (en) | Dexamethasone-cyproheptadine oral antiflammatory compositions | |
| RU2023109329A (ru) | Водный фармацевтический состав на основе гидрокортизона натрия фосфата и монотиоглицерина | |
| US20070259841A1 (en) | Combinations for the treatment of rheumatoid arthritis | |
| Call | Treatment of Adrenocorticosteroid Disorders | |
| Lötvall | Inhaled combination therapy with glucocorticoids and long-acting ß2-agonists in asthma and COPD, current and future perspectives |